IFW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313 on May 20, 2004

Frank C Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE STATEMENT
Examining Group
Patent Application
Docket No. G-078US05DIV
Serial No. 10/643,836

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Jean-Baptiste Dumas Milne Edwards, Lydie Bougueleret, Severin Jobert
Serial No.	:	10/643,836
Filed	:	August 18, 2003
For	:	Full-Length Human cDNAs Encoding Potentially Secrete Proteins

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.97 and §1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent application:

U.S. Serial No. 09/731,872, filed December 7, 2000, now abandoned.

The subject application, Serial No. 10/643,836, claims the benefit under 35 USC §120 of the filing date of the patent application Serial No. 09/731,872. Applicants respectfully request that the copies of references supplied in the Information Disclosure Statements of the 09/731,872 application, as well as references cited during the prosecution thereof, be made of record in the 10/643,836 application. As copies of the references filed in the 09/731,872 application, and cited on the attached form PTO/SB/08, can be found in the 09/731,872 casefile, copies of those references are not provided herewith.

It is respectfully requested that the references cited in the parent applications be considered in the examination of the subject application and that their consideration be made of record.

Applicants have also listed on form PTO/SB/08B numerous references which have not been cited the 09/731,872 application. Copies of the references are attached with this Information Disclosure Statement. Applicants respectfully request that these references be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,

Frank C Eisenschenk

Frank C. Eisenschenk
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/sl
Attachment: Form PTO/SB/08; copies of references cited therein

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 6

Complete if Known	
Application Number	10/643,836
Filing Date	August 18, 2003
First Named Inventor	J.-B. Dumas Milne Edwards
Art Unit	
Examiner Name	
Attorney Docket Number	G-078US05DIV

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. [1]	Document Number Number - Kind Code [2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-4,914,025	04/03/1990	Manoil *et al.*	All
	U2	US-5,536,637	07/16/1996	Jacobs	All
	U3	US-5,019,369	05/28/1991	Presant *et al.*	All
	U4	US-5,872,141	02/16/1999	Umbriet *et al.*	All
	U5	US-6,034,062	03/07/2000	Thies *et al.*	All
	U6	US-6,204,060	03/20/2001	Mehtali *et al.*	All
	U7	US-6,110,490	08/29/2000	Theirry	All
	U8	US-6,242,179	06/05/2001	Shah *et al.*	All
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. [1]	Foreign Patent Document Country Code [3] - Number [4] - Kind Code [5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [6]
	F1	EP 1130094 A2 (CD-ROM)	07/07/2000	Helix Research Institute	All	
	F2	WO 98/55614 A2	12/10/1998	Genetics Institute, Inc.	All	
	F3	WO 97/07198 A2	02/27/1997	Genetics Institute	All	
	F4	WO 97/04097 A2	02/06/1997	Genetics Institute	All	
	F5	WO 97/18826 A2	07/13/1995	Schering Corp.	All	
	F6					
	F7					

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known	
Application Number	10/643,836
Filing Date	August 18, 2003
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	
Examiner Name	
Attorney Docket Number	G-078US05DIV

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	R1	BOUGUELERET, L. *et al.* "Extended cDNAs Useful for Expressing Secreted Proteins and to Obtain Specific Antibodies", 2000, pp. 203-204, Accession No. AAY59685.	
	R2	CAMERON, C. *et al.* "Function and Protective Capacity of *Treponema Pallidum* Subsp. *Pallidum* Glycerophosphodiester Phosphodiesterase", *Infection and Immunity,* 1998, pp. 5763-5770, Vol. 66, No. 12, American Society for Microbiology.	
	R3	DOWNES, G. *et al.* "Structure and Mapping of the G Protein γ3 Subunit Gene and a Divergently Transcribed Novel Gene", *Gng31g*", *Genomics,* 1998, pp. 220-230, Vol. 53, Academic Press.	
	R4	INOUE, S. *et al.* "Growth Suppression of *Escherichia coli* by Induction of Expression of Mammalian Genes with Transmembrane or ATPase Domains", *Biochem. Biosphys. Reas. Comm.,* 2000, pp. 553-561, Vol. 268, Academic Press.	
	R5	JANSON, H. *et al.* "Protein D, the Glycerophosphodiester Phosphodiesterase from *Haemophilus influenzae* with Affinity for Human Immunoglobulin D, Influences Virulence in a Rat Otitis Model", *Infection and Immunity,* 1994, pp. 4848-4854, Vol. 62, No. 11, American Society for Microbiology.	
	R6	LARSON, T. *et al.* "Periplasmic Glycerophosphodiester Phosphodiesterase of *Escherichia coli,* a New Enzyme of the *glp* Regulon", *J. Biol. Chem.,* 1983, pp. 5428-5432, Vol. 258, No. 9.	
	R7	MAGRÉ, J. *et al.* "Identification Of The Gene Altered In Berardinelli-Seip Congenital Lipodystrophy On Chromosome 11q13", *Nature Genetics,* 2001, pp. 365-370, Vol. 28.	
	R8	MELDRUM, Brian "Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology", *The Journal of Nutrition – Supplement* (presented at the International Symposium on Glutamate, 1998), 2000, pp. 1007S-1015S, Pub: American Society for Nutritional Sciences.	
	R9	MUNSON, R. *et al.* "Protein D, a Putative Immunoglobulin D-Binding Protein Produced by *Haemophilus influenzae*, Is Glycerophosphodiester Phosphodiesterase", *J. Bacteriology,* 1993, pp. 4569-4571, Vol. 175, No. 14.	
	R10	NEER, Eva "Heterotrimeric G Proteins: Organizers of Transmembrane Signals", *Cell,* 1995, pp. 249-257, Vol. 80, Cell Press.	
	R11	SCHOEPP, D. *et al.* "Metabotropic Glutamate Receptors in Brain Function and Pathology", *TiPS,* 1993, pp. 13-20, Vol. 14, Elsevier Science Publishers, Ltd., UK.	
	R12	ZHENG, B. *et al.* "MIR16, a Putative Membrane Glycerophosphodiester Phosphodiesterase, Interacts with RGS16", *PNAS,* 2000, pp. 3999-4004, Vol. 97, No. 8.	
	R13	ZHENG, B. *et al.* "MIR16, a Putative Membrane Glycerophosphodiester Phosphodiesterase, Interacts with RGS16", *Proc. Natl. Acad. Sci. U.S.A.,* 2000, pp. 3999-4004, Vol. 97, No. 8, Accession No. AAF65234 (bases 1 to 331).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known	
Application Number	10/643,836
Filing Date	August 18, 2003
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	
Examiner Name	
Attorney Docket Number	G-078US05DIV

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	R14	ZHENG, B. *et al.* "MIR16, a Putative Membrane Glycerophosphodiester Phosphodiesterase, Interacts with RGS16", *Proc. Natl. Acad. Sci. U.S.A.*, 2000, pp. 3999-4004, Vol. 97, No. 8, Accession No. AF212862 (bases 1 to 1200).	
	R15	Glycerophosphoryl Diester Phosphodiesterase *Escherichia coli,* 1989, NiceProt View of SWISS-PROT: P10908.	
	R16	Glycerophosphoryl Diester Phosphodiesterase, periplasmic [Precursor] *Escherichia coli,* 1991, NiceProt View of SWISS-PROT: P09394.	
	R17	Glycerophosphoryl Diester Phosphodiesterase [Precursor] *Haemophilus influenzae,* 1995, NiceProt View of SWISS-PROT: Q06282.	
	R18	Similar to G Protein Gamma 3 Linked Gene *Homo Sapiens,* 2001, NiceProt View of SWISS-PROT: Q9BSQ0.	
	R19	Hypothetical 43.1 kDa protein *Mus musculus,* 2000, NiceProt View of SWISS-PROT: Q9JMF1.	
	R20	BORK, P. "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", *Genome Research,* 2000, pp. 398-400, Vol. 10.	
	R21	BROUN, P. *et al.*, "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity of Plant Lipids", *Science,* 1998, pp. 1315-1317, Vol. 282.	
	R22	SEFFERNICK,J.L. *et al.*, "Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different", *Journal of Bacteriology,* 2001, pp. 2405-2410, Vol. 183, No. 8, American Society for Microobiology.	
	R23	VAN DE LOO, F. J. *et al.*, "An Oleate 12-hydroxylase from Ricinus Communis L. is a Fatty Acyl Desaturase Homolog", *Proc. Natl. Acad. Sci. USA,* 1995, pp. 6743-6747, Vol. 92.	
	R24	WITKOWSKI, A. *et al.*, "Conversion of β-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine", *Biochemistry,* 1999, pp. 11643-11650, Vol. 38.	
	R25	ATTWOOD, T. "Genomics: The Babel of Bioinformatics", *Science,* 2000, pp. 471-473, Vol. 290, No. 5491.	
	R26	RUBEN S.M. *et al.* "Human Secreted Protein Encoded by Gene 21", *Database Geneseq* [online], March 23, 2000, AC No. Y76144, XP002163702.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Complete if Known	
Application Number	10/643,836
Filing Date	August 18, 2003
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	
Examiner Name	
Attorney Docket Number	G-078US05DIV

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	R27	RUBEN S.M. *et al.* "Human Secreted Protein Encoded by Gene 21", *Database Geneseq* [online], March 23, 2000, AC No. Z65270, XP002163703.	
	R28	*DATABASE EMBL*[online], AC No. AI911546, July 30, 1999, Natl. Cancer Inst., "ty73d05.x1 NCI_CGAP_Kid11 Homo Sapiens cDNA Clone IMAGE: 2284713", XP002163704.	
	R29	*DATABASE EMBL*[online], AC No. AI361251, January 7, 1999, Natl. Cancer Inst., "qy42e02.x1 NCI_CGAP_Brn23 Homo Sapiens cDNA Clone IMAGE: 2014682", XP002163705.	
	R30	JACOBS, K.A. *et al.* "A Genetic Selection for Isolating cDNAs Encoding Secreted Proteins", *Gene, NL, Elsevier*, October 1987, pp. 289-296, Vol. 198, Biomedical Press, Amsterdam, XP002045919.	
	R31	TASHIRO, K. *et al.* "Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type I Membrane Proteins", *Science*, July 30, 1993, pp. 600-603, Vol. 261, American Association for the Advancement of Science, XP000673204.	
	R32	LIM, E.M. *et al.* "Identification of Mycobacterium Tuberculosis DNA Sequences Encoding Exported Proteins by Using phoA Gene Fusions", *Journal of Bacteriology*, January 1995, pp. 59-650021-9193/95, Vol. 177, No. 1.	
	R33	MIYAKE *et al.* "RP105, a Novel B Cell Surface Molecule Implicated in B Cell Activation, is a Member of the Leucine-Rich Repeat Protein Family", *The Journal of Immunology*, pp. 3333-3340, The American Association of Immunologists, 0022-1767/95.	
	R34	JACOBS *et al.* "A Novel Method for Isolating Eukaryotic cDNA Clones Encoding Secreted Proteins", *Dendritic Cells: Antigen Presenting Cells of T and B Lymphocytes*, March 10-16, 1995, C1-207.	
	R35	FUJIWARA, T. *et al.* "HUM309B01B Clontech Human Aorta PolyA+ mRNA (#6572) Homo Sapiens cDNA Clone GEN-309B01 5', mRNA Sequence", XP002032351, Accession No. D62634.	
	R36	MARRA, M. *et al.* "The WashU-HHMI Mouse EST Project", XP002032348, Accession No. W08383.	
	R37	MARRA, M. *et al.* "The WashU-HHMI Mouse EST Project", XP002032350, Accession No. W11170.	
	R38	MARRA, M. *et al.* "The WashU-HHMI Mouse EST Project", XP002032349, Accession No. W17930.	
	R39	MARRA, M. *et al.* "The Wash U-HHMI Mouse EST Project", XP002032347, Accession No. W67046.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

Complete if Known	
Application Number	10/643,836
Filing Date	August 18, 2003
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	
Examiner Name	
Attorney Docket Number	G-078US05DIV

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	R40	ABRAHAM, E., *et al.*, "Phosphatidic Acid Signaling Mediates Lung Cytokine Expression and Lung Inflammatory Injury After Hemorrhage in Mice", *J. Exp. Med.*, 1995, pp. 569-575, Vol. 181.	
	R41	BRINDLEY, D. and WAGGONER, D. "Phosphatidate Phosphohydrolase And Signal Transduction", *Chem. Phys. Lipids*, 1996, pp. 45-57, Vol. 80.	
	R42	BURSTEN, S., *et al.*, "Potential Role for Phosphatidic Acid in Mediating the Inflammatory Responses to TNFα and IL-1β", *Circ. Shock*, 1994, pp. 14-29, Vol. 44.	
	R43	ENGLISH, D., "Phosphatidic Acid: A Lipid Messenger Involved in Intracellular and Extracellular Signalling", *Cell. Signal.*, 1996, pp. 341-347, Vol. 8, No. 5.	
	R44	ENGLISH, D., *et al.*, "Messenger Functions Of Phosphatidic Acid", *Chem. Phys. Lipids*, 1996, pp. 117-132, Vol. 80.	
	R45	KENT, C. "Eukaryotic Phospholipid Biosynthesis", *Ann. Rev. Biochem.*, 1995, pp. 315-343, Vol. 64.	
	R46	LEUNG, D., *et al.*, "CT-2576, An Inhibitor Of Phospholipids Signaling, Suppresses Constitutive And Induced Expression Of Human Immunodeficiency Virus", *Proc. Natl. Acad. Sci. USA*, 1995, pp. 4813-4817, Vol. 92.	
	R47	RICE, G., *et al.*, "Protection From Endotoxic Shock In Mice By Pharmacologic Inhibition Of Phosphatidic Acid", *Proc. Natl. Acad. Sci. USA*, 1994, pp. 3857-3861, Vol.91.	
	R48	ROBERTS, R. and MORRIS, A. "Role Of Phosphatidic Acid Phosphatase 2a In Uptake Of Extracellular Lipid Phosphate Mediators", *Biochimica et Biophysica Acta*, 2000, pp. 33-49, Vol. 1487.	
	R49	SALVADOR, G.A., *et al.*, "Differential Modulation Of Phospholipase D And Phosphatidate Phosphohydrolase During Aging In Rat Cerebral Cortex Synaptosomes", *Exp. Gerontology*, 2002, pp. 543-552, Vol. 37.	
	R50	STUKEY, J. and CARMAN, G. "Identification Of A Novel Phosphatase Sequence Motif", *Protein Science*, 1997, pp. 469-472, Vol. 6.	
	R51	Database GENBANK, Accession NP_003702; PANDEY, A.V., *et al.*, "Protein Phosphatase 2AAnd Phosphoprotein Set Regulate Androgen Production By p450c17", *J. Biol. Chem.*, 2003, pp. 2837-2844, Vol. 278, Issue 5.	
	R52	Database GENBANK, Accession No. NP_795714; PANDEY, A.V., *et al.*, "Protein Phosphatase 2A And Phosphoprotein SET Regulate Androgen Production By P450c17", *J. Biol. Chem.*, 2003, pp. 2837-2844, Vol. 278, Issue 5.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 6

Complete if Known	
Application Number	10/643,836
Filing Date	August 18, 2003
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	
Examiner Name	
Attorney Docket Number	G-078US05DIV

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	R53	Database GENBANK, Accession No. NP_803133; ISHIKAWA, T., *et al.*, "Cell Surface Activities Of The Human Type 2b Phosphatidic Acid Phosphatase", *J. Biochem.*, 2000, pp. 645-651, Volume 127, Issue 4.	
	R54	Database GENBANK, Accession No. NP_808211; ZHANG, N., *et al.*, "Mice Mutant For Ppap2c, A Homolog Of The Germ Cell Migration Regulator Wunen, Are Viable And Fertile", *Genesis*, 2000, pp. 137-140, Volume 27, Issue 4.	
	R55	Accession No. AAB70690, Human hDPP protein sequence SEQ ID NO:7, May 17, 2001.	
	R56		
	R57		
	R58		
	R59		
	R60		
	R61		
	R62		
	R63		
	R64		
	R65		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.